Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human metabolome at a rate is unmatched for discovery, uncovering previously unknown biomarkers that associate with early disease detection, disease progression, and drug response.

By enabling sponsors rapidly identify, validate, and translate these novel biomarkers, we help accelerate their drug development programs, enrich clinical trials, and align patients, specific disease pathobiology, and specific, efficacious therapies. How do we do it?

Rapid liquid chromatography-mass spectrometry (rLC-MS) – our proprietary systems enable ultra high throughput, population-level biomarker discovery, capturing and measuring >11K small molecule biomarkers (both known and unknown) per sample, in <1 minute analytical cycle time.

Biocomputational integration – our expert team of data scientists apply statistical and machine learning tools to rapidly identify key biomarkers of interest, integrating our spectral data with other high dimensional data from preclinical models, genomics, proteomics, and clinical studies.

Human Biology Database – encompassing data from >100,000s of human biosamples for cross-validation of biomarkers in large, independent populations.

Discover why Sapient is the metabolomics CRO you want to partner with, and how we can work together to advance your drug programs, at any phase. Use the form to schedule a time to talk to our scientists.

Untargeted Metabolomics Services for an Unprecedented Scale of Biomarker Discovery

Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human metabolome at a rate is unmatched for discovery, uncovering previously unknown biomarkers that associate with early disease detection, disease progression, and drug response. By enabling sponsors rapidly identify, validate, and translate these novel biomarkers, we… Read More